Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-methyl-5-(2-phenoxymethyl-pyrrolidine-1-sulfonyl)-1H-indole-2,3-dione is a synthetic small molecule belonging to the indole and isatin sulfonamide class. It has been studied primarily as an experimental inhibitor of caspase enzymes—particularly caspase-3—which are cysteine proteases involved in apoptosis (programmed cell death). The compound acts by binding to and inhibiting the activity of these proteases. There are no approved therapeutic indications or marketed products containing this compound; it remains an experimental research tool for studying apoptosis pathways and potential anti-apoptotic interventions[2][4][6]. No clinical trials or approvals have been reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-methyl-5-(2-phenoxymethyl-pyrrolidine-1-sulfonyl)-1H-indole-2,3-dione.